CRISPR Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
CRISPR Therapeutics announced participation in the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15, 2022, at 9:20 a.m. PT. Senior management members will present insights on the company's advancements in gene-based medicines for serious diseases, leveraging the CRISPR/Cas9 technology. A live webcast of the presentation will be accessible on their Investors page, with a replay available for 14 days post-event. CRISPR Therapeutics continues to develop therapies across various sectors, including oncology and rare diseases, collaborating with major partners like Bayer and Vertex Pharmaceuticals.
- None.
- None.
ZUG, Switzerland and CAMBRIDGE, Mass., June 08, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on Wednesday, June 15, 2022, at 9:20 a.m. Pacific Time (PT).
A live webcast of the presentation will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
CRISPR THERAPEUTICS® word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.
Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com
Media Contact:
Rachel Eides
+1-617-315-4493
rachel.eides@crisprtx.com
FAQ
What is CRSP's event on June 15, 2022?
Where can I watch the CRSP conference presentation?
How long will the CRSP webcast be available after the event?
What is the focus of CRISPR Therapeutics?
What are the key partnerships for CRSP?
